



**THE FOUNDATION
FOR SECURE
MARKETS®**

#54650

Date: May 30, 2024

Subject: Adjusted Inhibrx, Inc. - Further Adjustment
Adjusted Option Symbol: INBX1
Date: 05/30/2024

Adjusted Inhibrx Biosciences, Inc. Options were adjusted on May 30, 2024 (See OCC Information Memo #54648). The new deliverable became 1) 100 Inhibrx, Inc. Common Shares and 2) 25 (New) Inhibrx Biosciences, Inc (INXB) Common Shares.

On May 24, 2024, Shareholders of Inhibrx, Inc. (INBX) voted concerning the Plan of Merger with Sanofi (SNY). The merger was approved and subsequently consummated before the open on May 30, 2024. As a result, each existing INBX Common Share will be converted into the right to receive \$30.00 net cash plus one non-transferable contingent value right (CVR).

Note: The CVR represents a non-transferable contractual right to receive additional payments. The adjusted INBX option deliverable will not include the non-transferable CVRs.

The new Inhibrx Biosciences, Inc. Common Shares began trading regular way on Nasdaq on May 30, 2024 under the trading symbol "INXB", and will change from "INXB" to "INBX" on May 31, 2024.

Adjusted Inhibrx Biosciences, Inc. options will be further adjusted as described below:

Contract Adjustment

Date: May 30, 2024

Option Symbol: INBX1 remains INBX1

Strike Divisor: 1

Contracts Multiplier: 1

New Multiplier: 100 (e.g., a premium of 1.50 yields \$150; a strike of 35 yields \$3,500.00)

New Deliverable Per Contract: 1) 25 (New) Inhibrx Biosciences, Inc. (INXB) Common Shares.
2) \$3,000.00 cash (\$30.00 x 100)

Note: The underlying equity symbol will change from INXB to INBX on May 31, 2024.

CUSIP: INXB: (New) 45720N103

Pricing

The underlying price for INBX1 will be determined as follows:

$$\text{INBX1} = 0.25 (\text{INXB}) + 30.00$$

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.